Skip to content

The effect of simvastatin on plasma amyloid-beta transport in patients with hypercholesterolemia

The effect of simvastatin on plasma amyloid-beta transport in patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014937
Enrollment
Unknown
Registered
2018-02-23
Start date
2018-03-01
Completion date
Unknown
Last updated
2018-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

1:simvastatin 40mg po qn
2:placebo 40mg po qn

Sponsors

The First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Ages 50~65 years male and female; 2. In the last 30 days, serum lipid level in the morning was consistent with the diagnostic criteria of hypercholesterolemia at least twice, that is total serum cholesterol concentration = 5.18 mmol/L and (or) serum low-density lipoprotein cholesterol concentration = 3.37 mmol/L; 3. Without contraindications to simvastatin; 4. The provision of informed consent for study participation.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Secondary hyperlipidemia; 3. Taking lipid-lowering drugs or other drugs which could affect both lipid and plasma biomarkers in last 14 days; 4. Allergic constitutions or be allergic to statins; 5. Heavy drinking, active hepatitis and patients with unexplained elevated aminotransferase; 6. Non-cooperative individuals.

Design outcomes

Primary

MeasureTime frame
Aß1-40;Aß1-42;

Secondary

MeasureTime frame
sLRP1;sRAGE;

Countries

China

Contacts

Public ContactQu Qiumin

The First Affiliated Hospital of Xi'an Jiaotong University

quqiumin@126.com+86 13892898562

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026